SCHEDULE: FMR LLC Discloses Stake in Janux Therapeutics

FMR LLC has reported beneficial ownership of 4.2% of Janux Therapeutics Inc.'s common stock as of March 31, 2026.

Summary

• FMR LLC, along with its affiliates and subsidiaries (collectively, the "FMR Reporters"), has filed a Schedule 13G, indicating their beneficial ownership of Janux Therapeutics Inc. common stock.
• As of March 31, 2026, the FMR Reporters beneficially owned 2,535,723.63 shares, representing 4.2% of the class of securities.
• FMR LLC holds sole voting power for 2,526,810.00 shares and sole dispositive power for 2,535,723.63 shares.
• Abigail P. Johnson, Director, Chairman, and CEO of FMR LLC, is also identified. Members of the Johnson family are predominant owners of FMR LLC's Series B voting common shares.
• The filing states that no single other person's interest in Janux Therapeutics' common stock exceeds five percent of the total outstanding shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of beneficial ownership by an institutional investor and does not provide new operational or financial information about Janux Therapeutics.

Positives

• FMR LLC, a significant institutional investor, has disclosed a substantial stake in Janux Therapeutics, which can be viewed as a positive signal of confidence in the company's prospects.
• The filing indicates that FMR LLC holds significant voting and dispositive power, suggesting active engagement or a strategic investment approach.

Negatives

• The filing does not contain any negative financial results or operational challenges for Janux Therapeutics; it is purely an ownership disclosure.

Risks

• The filing does not explicitly mention any risks related to Janux Therapeutics' business operations or financial health. The primary 'risk' from an investor perspective would be the general market risk associated with any equity investment.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Janux Therapeutics' future performance.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "No one other person's interest in the COMMON STOCK of JANUX THERAPEUTICS INC is more than five percent of the total outstanding COMMON STOCK."
• "Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC."

Industry Context

StockSavvy.ai notes that the filing of a Schedule 13G by a major institutional investor like FMR LLC signifies a passive investment stake, typically below 5% or for investment purposes rather than control. This is a common occurrence in the biotechnology and pharmaceutical sectors where significant capital is required, attracting diverse investor bases.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's passive stake, which may be viewed positively by some as validation, but it does not directly impact current operations or strategy.
• Management: The filing is a standard regulatory requirement and does not directly impose new demands on Janux Therapeutics' management beyond compliance.

Next Steps

• FMR LLC will continue to monitor its beneficial ownership stake in Janux Therapeutics Inc. and will file amendments to this Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Janux Therapeutics, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management